Disc Medicine Wins Analyst Backing on Blood Disorder Trial Data
Jefferies and BMO both reaffirmed their ratings on Disc Medicine after new data on its polycythemia treatment, with BMO keeping an Outperform call.
Two brokerages reiterated favorable ratings on Disc Medicine following trial data for its polycythemia treatment, a disorder marked by excess red blood cells.
BREAKING STORYBULLISH